Updates – December 2023
Annogen has signed a deal with an undisclosed gene therapy company for an AAV capsid screening project. For this project, Annogen will deliver its SuRE™ barcoding platform and downstream bioinformatics analysis to track tissue-specific biases for many capsids in parallel.
Capsids are the protein shells of the adeno associated virus (AAV). In AAV gene therapy, the capsid serves as the vehicle for transporting the therapeutic genetic payload into the target cells. The capsid plays a pivotal role in determining the virus’s ability to enter specific cell types, evade the immune system, and successfully deliver the therapeutic genes to the desired location within the host organism. Consequently, ongoing research in the field focuses on refining capsid design to improve cell-type specific delivery of AAV gene therapy treatments.
Given their role in achieving cell-type specific therapies, capsids are – along with cell-type specific gene promoters – essential for the success of AAV-based gene therapies by minimizing potential adverse effects.
Annogen is pleased to now also offer this service in the gene therapy field alongside our screening platform for cell-type specific promoters. For more information contact Victor Schut, CBO at [email protected].
